ASSESSMENT OF COGNITIVE FUNCTION IN MYASTHENIC PATIENTS (LITERATURE REVIEW)

Abstract

Myasthenia gravis is an autoimmune disease caused by destruction of nicotinic acetylcholine receptors on the motor endplates of the transverse striated muscles. The incidence ranges from 1 to 9 cases per million in the general population. The prevalence of MG ranges from 15 to 179 cases per million population worldwide. Although it is predominantly a muscular disease, cognitive impairment in patients with myasthenia gravis has been discussed in the literature. Some studies have found cognitive decline in attention memory, executive functions, verbal fluency, and planning tasks. However, there are other studies that have found no differences in the cognitive functions of myasthenia gravis patients compared to healthy controls.